ClearPoint Neuro Shares Rise 32% to $17.66
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 17 2026
0mins
Shares of ClearPoint Neuro (CLPT) are up $4.32, or 32%, to $17.66 in pre-market trading after partner uniQure (QURE) announced during a recent Type B meeting with the FDA that the previously reported three-year data from the Phase I/II study would be acceptable for a BLA submission for the accelerated approval of AMT-130 in Huntington's disease.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CLPT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CLPT
Wall Street analysts forecast CLPT stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 18.720
Low
28.00
Averages
29.00
High
30.00
Current: 18.720
Low
28.00
Averages
29.00
High
30.00
About CLPT
ClearPoint Neuro, Inc. is a commercial-stage medical device company that develops and commercializes integrated systems used in minimally invasive neurosurgical procedures in the brain. The Company provides clinical products and preclinical development services for controlled drug and device delivery. Its business consists of two components: a business providing medical devices for neurosurgical applications, and a business focused on partnerships in the biologics and drug delivery space. Its primary medical device product, the ClearPoint system, is an integrated system comprised of hardware components, disposable components, and intuitive, menu-driven software. The primary applications for the ClearPoint system are to target and guide the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, and the infusion of pharmaceuticals into the brain. It provides consulting services to its pharmaceutical and other medical technology partners.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
uniQure Shares Surge After FDA Softens Stance on Gene Therapy
- FDA Policy Shift: uniQure N.V. (QURE) shares surged 78.44% to $48.16 after the FDA accepted the 3-year analysis from its Phase I/II study as the primary basis for a Biologics License Application for AMT-130 in Huntington's disease, marking a significant regulatory milestone.
- Positive Cancer Vaccine Responses: Elicio Therapeutics Inc. (ELTX) reported that three patients in its Phase 2 AMPLIFY-7P study showed excellent responses to the experimental vaccine ELI-002 7P, leading to a 70.65% stock increase to $4.71, indicating potential for enhanced immunotherapy effectiveness.
- Key Company Developments: Lunai Bioworks (LNAI) saw its shares rise 40.06% to $4.00 as the CEO highlighted significant advancements, including a U.S. government defense contract and the development of an AI-driven precision neurology pipeline, positioning the company strategically in biotech and national security.
- Patent Application Boost: Polyrizon Ltd. (PLRZ) shares increased by 15.55% to $13.23 following the publication of a U.S. patent application for its nasal drug delivery technology, showcasing its innovative capabilities in the biotech sector and potential market impact.
See More
NeOnc Technologies Secures International Drug Authorization for NEO212
- International Drug Authorization: NeOnc Technologies has secured Investigational New Drug authorization for NEO212 from the Abu Dhabi Department of Health, marking a significant milestone in neuro-oncology and expected to accelerate its global market expansion.
- Clinical Trial Progress: The Phase 2a study for NEO100 has achieved full enrollment, with preliminary data indicating approximately 24% tumor remission in recurrent glioblastoma patients, showcasing the potential market value of this therapy.
- Insider Investment Confidence: CEO Amir Heshmatpour has personally invested over $500,000 recently, reflecting strong management confidence in the company's future, with total insider purchases nearing $1 million over the past year.
- Financial Support: NeOnc Technologies has access to a $75 million at-the-market facility and a $10 million line of credit, providing robust financial backing for advancing multiple clinical programs.
See More
ClearPoint Neuro Reports Record Q1 2026 Revenue Amid Integration Progress
- Record Revenue: ClearPoint Neuro achieved a record revenue of $12.1 million in Q1 2026, representing a 43% year-over-year increase, with organic device growth of 25%, indicating strong performance in the neurosurgery navigation market and potential for increased market share.
- Acquisition Integration Progress: The majority of post-merger integration costs from the IRRAS acquisition were completed in Q1, with management stating that significant revenue and cost synergies will continue, and operational cash burn is expected to decrease in the coming quarters, enhancing financial stability.
- FDA New Product Approval: The company received FDA clearance for the Velocity Alpha MR high-speed surgical drill system and CE marking in Europe, marking an expansion of its product line and expected to provide strong support for future revenue growth.
- 2026 Outlook: Management expects revenue for 2026 to be in the range of $52 million to $56 million, with all four business segments anticipated to grow in double digits, reflecting confidence in future market demand.
See More
ClearPoint Neuro Q1 Earnings Beat Expectations Despite EPS Miss
- Earnings Highlights: ClearPoint Neuro reported a Q1 GAAP EPS of -$0.32, missing estimates by $0.05, yet revenue reached $12.13 million, a 42.9% year-over-year increase, surpassing expectations by $0.16 million, indicating strong growth potential in the market.
- Cash Flow Status: As of March 31, 2026, the company had cash and cash equivalents totaling $35.6 million, down from $45.9 million at December 31, 2025, primarily due to $8.0 million in cash used for operating activities and $2.0 million in tax payments related to equity awards, reflecting pressure on cash management.
- Acquisition Synergies: The company anticipates that cost synergies from the acquisition of IRRAS will contribute to a reduction in cash burn in the second half of 2026, believing that asset integration could potentially be cash neutral for the full year 2027, demonstrating confidence in future financial health.
- Business Outlook: ClearPoint Neuro estimates revenue for 2026 to be between $52.0 million and $56.0 million, below the analyst consensus of $53.3 million; nevertheless, the company's long-term outlook remains optimistic, showcasing its competitive position in the industry.
See More
ClearPoint Neuro Q1 Earnings Announcement Scheduled
- Earnings Announcement Date: ClearPoint Neuro, Inc. is set to announce its Q1 earnings on May 13th after market close, with a consensus EPS estimate of -$0.27 and a revenue estimate of $11.97 million, indicating challenges in profitability.
- Earnings Estimate Revisions: Over the past three months, there have been no upward revisions to EPS estimates, with two downward adjustments, while revenue estimates also saw no upward revisions and two downward changes, reflecting market caution regarding the company's short-term performance.
- Long-Term Outlook: Despite facing temporary headwinds, ClearPoint Neuro has outlined a revenue target of $52 million to $56 million for 2026, demonstrating the company's commitment to advancing its growth strategy and integrating the IRRAS acquisition.
- Market Reaction: The company's FY26 guidance fell below analysts' estimates, leading to a significant drop in stock price, highlighting investor concerns about the company's future performance.
See More
ClearPoint Neuro and UniQure Stocks Surge Following WSJ Report on Trump's Potential Plan to Dismiss FDA Commissioner Marty Makary
Company Overview: ClearPoint Neuro and Uniqure are involved in the biotechnology sector, focusing on innovative solutions in neurotechnology.
Market Reaction: Shares of ClearPoint Neuro have seen a significant increase following reports from the Wall Street Journal regarding potential changes in leadership at the FDA.
Leadership Changes: The reports suggest that former President Trump is considering firing FDA Commissioner Marty Makary, which has implications for regulatory processes in the biotech industry.
Investor Sentiment: The news has sparked interest among investors, leading to a spike in ClearPoint Neuro's stock prices as market participants react to the potential shifts in FDA oversight.
See More
uniQure Shares Surge After FDA Softens Stance on Gene Therapy
- FDA Policy Shift: uniQure N.V. (QURE) shares surged 78.44% to $48.16 after the FDA accepted the 3-year analysis from its Phase I/II study as the primary basis for a Biologics License Application for AMT-130 in Huntington's disease, marking a significant regulatory milestone.
- Positive Cancer Vaccine Responses: Elicio Therapeutics Inc. (ELTX) reported that three patients in its Phase 2 AMPLIFY-7P study showed excellent responses to the experimental vaccine ELI-002 7P, leading to a 70.65% stock increase to $4.71, indicating potential for enhanced immunotherapy effectiveness.
- Key Company Developments: Lunai Bioworks (LNAI) saw its shares rise 40.06% to $4.00 as the CEO highlighted significant advancements, including a U.S. government defense contract and the development of an AI-driven precision neurology pipeline, positioning the company strategically in biotech and national security.
- Patent Application Boost: Polyrizon Ltd. (PLRZ) shares increased by 15.55% to $13.23 following the publication of a U.S. patent application for its nasal drug delivery technology, showcasing its innovative capabilities in the biotech sector and potential market impact.
See More
NeOnc Technologies Secures International Drug Authorization for NEO212
- International Drug Authorization: NeOnc Technologies has secured Investigational New Drug authorization for NEO212 from the Abu Dhabi Department of Health, marking a significant milestone in neuro-oncology and expected to accelerate its global market expansion.
- Clinical Trial Progress: The Phase 2a study for NEO100 has achieved full enrollment, with preliminary data indicating approximately 24% tumor remission in recurrent glioblastoma patients, showcasing the potential market value of this therapy.
- Insider Investment Confidence: CEO Amir Heshmatpour has personally invested over $500,000 recently, reflecting strong management confidence in the company's future, with total insider purchases nearing $1 million over the past year.
- Financial Support: NeOnc Technologies has access to a $75 million at-the-market facility and a $10 million line of credit, providing robust financial backing for advancing multiple clinical programs.
See More
ClearPoint Neuro Reports Record Q1 2026 Revenue Amid Integration Progress
- Record Revenue: ClearPoint Neuro achieved a record revenue of $12.1 million in Q1 2026, representing a 43% year-over-year increase, with organic device growth of 25%, indicating strong performance in the neurosurgery navigation market and potential for increased market share.
- Acquisition Integration Progress: The majority of post-merger integration costs from the IRRAS acquisition were completed in Q1, with management stating that significant revenue and cost synergies will continue, and operational cash burn is expected to decrease in the coming quarters, enhancing financial stability.
- FDA New Product Approval: The company received FDA clearance for the Velocity Alpha MR high-speed surgical drill system and CE marking in Europe, marking an expansion of its product line and expected to provide strong support for future revenue growth.
- 2026 Outlook: Management expects revenue for 2026 to be in the range of $52 million to $56 million, with all four business segments anticipated to grow in double digits, reflecting confidence in future market demand.
See More
ClearPoint Neuro Q1 Earnings Beat Expectations Despite EPS Miss
- Earnings Highlights: ClearPoint Neuro reported a Q1 GAAP EPS of -$0.32, missing estimates by $0.05, yet revenue reached $12.13 million, a 42.9% year-over-year increase, surpassing expectations by $0.16 million, indicating strong growth potential in the market.
- Cash Flow Status: As of March 31, 2026, the company had cash and cash equivalents totaling $35.6 million, down from $45.9 million at December 31, 2025, primarily due to $8.0 million in cash used for operating activities and $2.0 million in tax payments related to equity awards, reflecting pressure on cash management.
- Acquisition Synergies: The company anticipates that cost synergies from the acquisition of IRRAS will contribute to a reduction in cash burn in the second half of 2026, believing that asset integration could potentially be cash neutral for the full year 2027, demonstrating confidence in future financial health.
- Business Outlook: ClearPoint Neuro estimates revenue for 2026 to be between $52.0 million and $56.0 million, below the analyst consensus of $53.3 million; nevertheless, the company's long-term outlook remains optimistic, showcasing its competitive position in the industry.
See More
ClearPoint Neuro Q1 Earnings Announcement Scheduled
- Earnings Announcement Date: ClearPoint Neuro, Inc. is set to announce its Q1 earnings on May 13th after market close, with a consensus EPS estimate of -$0.27 and a revenue estimate of $11.97 million, indicating challenges in profitability.
- Earnings Estimate Revisions: Over the past three months, there have been no upward revisions to EPS estimates, with two downward adjustments, while revenue estimates also saw no upward revisions and two downward changes, reflecting market caution regarding the company's short-term performance.
- Long-Term Outlook: Despite facing temporary headwinds, ClearPoint Neuro has outlined a revenue target of $52 million to $56 million for 2026, demonstrating the company's commitment to advancing its growth strategy and integrating the IRRAS acquisition.
- Market Reaction: The company's FY26 guidance fell below analysts' estimates, leading to a significant drop in stock price, highlighting investor concerns about the company's future performance.
See More
ClearPoint Neuro and UniQure Stocks Surge Following WSJ Report on Trump's Potential Plan to Dismiss FDA Commissioner Marty Makary
Company Overview: ClearPoint Neuro and Uniqure are involved in the biotechnology sector, focusing on innovative solutions in neurotechnology.
Market Reaction: Shares of ClearPoint Neuro have seen a significant increase following reports from the Wall Street Journal regarding potential changes in leadership at the FDA.
Leadership Changes: The reports suggest that former President Trump is considering firing FDA Commissioner Marty Makary, which has implications for regulatory processes in the biotech industry.
Investor Sentiment: The news has sparked interest among investors, leading to a spike in ClearPoint Neuro's stock prices as market participants react to the potential shifts in FDA oversight.
See More
